Covid-19
Russia’s COVID-19 vaccine Sputnik V to be produced in Italy
The Russian COVID-19 vaccine, Sputnik V, is to be produced in Italy from this summer, the Italian-Russian chamber of commerce said on Tuesday.
A subsidiary of Swiss pharmaceutical company Adienne Pharma and Biotech is to produce the vaccine in Lombardy.
Up to 10 million doses could be produced there by the end of the year, according to the statement.
This is the first deal between a European partner and RDIF, the Russian direct investment fund behind Sputnik V, the chamber of commerce said in its statement.
According to the ANSA news agency, Vincenzo Trani, head of the chamber of commerce, said the production of the vaccine did not mean it would also be immediately distributed, and Italy was still collaborating with the European Union in that regard.
Health Minister Roberto Speranza, said over the weekend that he was “open towards the Russian Sputnik vaccine’’ if it is approved by EU health authorities.
The European Medicines Agency (EMA) is currently reviewing Sputnik V for approval in the bloc.
Christa Wirthumer-Hoche, a representative of the agency, on Sunday warned EU states of approving the Russian vaccine before the EMA has reviewed its data, calling it a “Russian roulette.’’
Russia on Tuesday criticised the EMA for those comments.
“Vaccines and the EMA should stand above and beyond politics,’’ said a statement posted on the Sputnik V Telegram channel.
-
Football6 days agoSaka: England still carry World Cup scar
-
Latest3 days agoPastor Chris Oyakhilome announces mother’s passing at 88 [VIDEO]
-
Latest5 days agoArsenal eye €70-80m move for Real Madrid star
-
Business1 week agoCBN reduces MPR by 350bps to 23% in major monetary policy shift
-
Crime4 days agoPolice arrest suspect, launch manhunt for 2 others over Delta Education Director’s death
-
Latest4 days agoHow adulterated palm oil, coloured pepper are putting consumers at risk
-
Crime3 days agoDeaths in NSCDC Custody: Can Nigeria guarantee the safety of detainees?
-
Latest5 days agoObi left $155m in Anambra, Otti insists amid debt controversy


